Terns Pharmaceuticals Inc.’s stock jumped 7.5% premarket Tuesday, after the company announced positive data from an early-stage trial of a treatment for chronic myeloid leukemia.
Terns Pharma broadens beyond obesity drugs with upbeat data in leukemia trial
